VTRS

Viatris Inc Ord Shs

15.90

+0.34+2.19%

After Hours: 15.91 +0.01 +0.06%16:36 06/04 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE15.70/15.56

TODAY RANGE15.64-15.99

VOL7.46M

MARKET CAP18.52B

52 WEEK RANGE8.08-17.40

AVG VOL (3M)10.91M

% TURNOVER0.64%

TURNOVER--

P/E (TTM)-61.4137

% RANGE2.25%

EPS(TTM)-0.2589

P/E(FORWARD)86.09

P/B1.263

BVPS12.59

DIVIDEND0.4800

P/S1.280

BETA--

DIV YIELD3.02%

FREE FLOAT MKT CAP18.46B

SHARES OUTSTANDING1.16B

NEXT EARNINGS08/05-08/10

FREE FLOAT1.16B

LOT SIZE1

EX-DATE05/22/2026

News

Press Releases

Financial Reports

Profile

TipRanks·7h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viatris (VTRS), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX)
TipRanks·7h ago
Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)
PUBT·2d ago
Salesforce says Viatris selects Agentforce Life Sciences as global customer engagement platform
Seeking Alpha·3d ago
These 10 large-cap healthcare giants rank among the market's most attractively valued stocks
TipRanks·6d ago
Piper Sandler Remains a Hold on Viatris (VTRS)
Seeking Alpha·05/28 17:36
Consumers could pay less for drugs with Mark Cuban pharmacy than own insurance
Seeking Alpha·05/28 08:09
90 Top Ten-Year Dog Collection Yields 22 Ideal Buys From 41 'Safer' Sorts In May
Reuters·05/19 10:32
VIATRIS INC. <VTRS.O>: BARCLAYS RAISES TARGET PRICE TO $22 FROM $17
Dow Jones·05/19 10:13
Viatris Is Maintained at Overweight by Barclays
Dow Jones·05/19 10:13
Viatris Price Target Raised to $22.00/Share From $17.00 by Barclays
TipRanks·05/19 09:20
Viatris price target raised to $22 from $17 at Barclays
TipRanks·05/19 08:37
Barclays Remains a Buy on Viatris (VTRS)
Reuters·05/19 07:56
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Seeking Alpha·05/18 20:03
TrumpRx set to expand into generic medicines with Mark Cuban
NASDAQ·05/18 14:51
Noteworthy ETF Outflows: DFAT, PR, VTRS, CF

Same Industry

Name/Symbol

Change%

Price

VTRS

MCK

Biogen Inc

BIIB

-0.20%

196.00

AMGN

SHPG

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+0.26%

0.1153

LLY

CELG

Therapeuticsmd Inc

TXMD

+2.54%

2.020

JNJ

Abbvie Inc

ABBV

-0.42%

217.72

ZTS

Gilead Sciences Inc

GILD

-2.13%

128.31

Novo-Nordisk A/S

NVO

+0.15%

45.58

Bristol-Myers Squibb Co

BMY

+0.47%

57.18

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

-2.10%

25.63

SNY

GCVRZ

Novartis

NVS

-0.81%

150.17

Dr Reddys Labs

RDY

+0.81%

13.63

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.